Calimmune

CSL Behring to acquire Calimmune for $91M

Monday, August 28, 2017

Global biotherapeutics provider CSL Behring has agreed to acquire Calimmune, a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, and Sydney, Australia, for an upfront payment of $91 million. 

[Read More]